Pancreatic solid serous cystadenoma treated by laparoscopy: Presentation of a new case report and review of the literature

Mohamed Hamid a,∗, Mohamed Tbouda b, Anass Mohamed Majbar a, Mohamed Raiss a, Mohamed Ahallat a

a Department of Surgery «C», Ibn Sina Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Morocco
b Department of Anatomopathology, Ibn Sina Hospital, Mohammed V University of Rabat, Faculty of Medicine and Pharmacy, Morocco

ARTICLE INFO

Article history:
Received 23 August 2017
Accepted 3 September 2017
Available online 23 September 2017

Keywords:
Solid serous cystadenoma
Serous cystadenoma
Pancreas
Surgery
Laparoscopy
Case report

ABSTRACT

Solid serous cystadenoma is an uncommon benign pancreatic tumor, with only, including this case, 21 cases published so far. It is often misdiagnosis with other malignant pancreatic tumors.

Below we report a new case of a solid serous cystadenoma of the pancreas treated by laparoscopic distal pancreatectomy in 53-year-old female who presented with epigastric pain. Histological and immunohistochemical examination revealed a solid serous cystadenoma of the pancreas. Preoperative diagnosis of this subtype of serous cystadenoma is difficult, and, due to its benign nature, conservative resection of the tumor is the recommended treatment.

After analyzing the literature, including this case from our department, we discuss clinical presentation, imaging characteristics and histopathological findings, considering in particular difficulties in preoperative diagnosis, feasibility of laparoscopic resection.

© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The discovery of a solid pancreatic tumor can lead to the diagnosis of a very varied histological lesion and prognosis. Typically, solid tumors of the pancreas are associated with malignancy, whereas cystic tumors more often tend to be benign [1,2]. The challenge is to determine if there is a malignant tumor (adenocarcinoma, metastases...)? or benign (solid pseudopapillary tumor (SPT), neuroendocrine tumor (NET), autoimmune pancreatitis...) [2].

Perez-Ordóñez and al, described in 1996, a particular form of pancreatic serous cystic tumor with solid appearance and called it solid serous cystadenoma (SSCA) [3], it is by far the rarest subtype of serous cystic neoplasm (SCN), with only, including this case, 21 cases published so far.

Apart from other subtypes of SCN with cyst morphology, SSCA is a solid pancreatic tumor, its architecture is different from that of a serous cystadenoma (SCA), but their cytological, immunological, and histopathological characteristics are identical [4], leading to difficulty in preoperative diagnostic by imaging studies [5]. SSCA is difficult to distinguish from other solid tumors[5–8]. The knowledge of this histological type is important because, in epidemiology and imaging, its characteristics resemble to those of other solid tumors such as pancreatic adenocarcinomas, NET, solid pseudopapillary tumor and renal cell carcinoma metastasis, but the management and prognosis of these diseases are totally different.

The preoperative diagnosis of SSCA is challenging because of its rarity. However, the absence of malignancy signs should consider a conservative management; as the lesion is benign, minimal invasive surgery should be [2,9].

After analyzing the literature, including this case from our surgery department, we discuss clinical presentation, imaging characteristics and histopathological findings, considering in particular difficulties in preoperative diagnosis, feasibility of laparoscopic resection.

The work in this case has been reported in line with the SCARE criteria [10].

2. Presentation of case

A 53-year-old woman presented to our institute with 6 mounts fixed epigastric pain, gradually increasing in intensity with episodes of nausea and vomiting. She had no other symptoms and was free from any underlying disease.

Her past medical history was unremarkable unless a caesarean section 16 years ago, and was not taking any medications. The patient had an unremarkable family history.

The patient was completely fit, BMI = 22.5 kg/m2, and her vital signs were normal. Physical examination revealed mild abdominal pain at the epigastrum.
Laboratory examination showed the following: WBC 4770/ml, Hb 12.3 g/dl, platelet count 263,000/ml, Albumin 42 g/l, IB 11 mg/l, DB 5 mg/l, Lipase 14 UI, Creatinine 7.2 mg/l, serum markers of exocrine and endocrine pancreatic tumors were normal (carcinoembryonic antigen (CEA): 3.9 ng/mL, reference range: 0–5 ng/mL; carbohydrate antigen 19-9 (CA19-9): 6.4 U/mL reference range: 0–27 U/mL).

Abdominal ultrasonography showed a tissular well circumscribed hypoechoic mass, 3 by 2 cm in diameter, at the pancreatic body.

An abdominal CT scan confirmed the presence of a 3.5 cm diameter well defined solid polycyclic mass at the pancreatic body, hypodense in the pre-contrast phase as compared to the surrounding pancreatic tissue (20–40 HU), without a dilatation of the distal pancreatic duct (Fig. 1a). In the portal phase, weak tumor enhancement (80–100 HU) compared with the adjacent normal pancreatic tissues (70 HU) (Fig. 1b). The central part of the tumor was consistently poorly enhanced throughout the scan. There was no honeycomb appearance, central scarring, or stellate calcification. There was no local invasion neither lymphadenopathies.

The diagnosis of solid mass of the pancreatic body was made. The differential diagnosis included pancreatic NET, solid pseudopapillary tumor and metastatic carcinoma. The diagnosis of ductal pancreatic adenocarcinoma was excluded in front of its morphological characteristics (well circumscribed, does not show contrast enhancement in the early phase, without vascular involvement neither coeliac lymphadenopathies). So, a laparoscopic approach is proposed.

The patient underwent a laparoscopic surgery. Intraoperatively, a well-encapsulated polycyclic mass was recognized at the pancreatic body (Fig. 2), the adjacent pancreatic tissue was completely normal, there was no local invasion neither macroscopic lymphadenopathies. A distal pancreatectomy with splenectomy via a medial-to-lateral approach was performed. The pancreas was approached through the gastrocolic ligament into the lesser sac. The retroperitoneum overlying the inferior border of the pancreas is dissected. The splenic artery and vein were identified and clipped near to the celiac trunk (Fig. 3). The short gastric vessels are taken down to fully retract the stomach. The pancreatic body was divided by a 60-mm green stapler (Fig. 4).

Macroscopically, the resection specimen showed a solid whitish, well circumscribed, encapsulated mass, measuring 3 × 1 × 1 cm, located in the pancreatic body, 1.5 cm from the pancreatic surgical margin (Fig. 5a). The surrounding pancreatic parenchyma was normal and surgical margins were negative. The tumor contained a thick fibrous band without necrosis or hemorrhage. Histological
examination showed a very limited and encapsulated tumor proliferation made of tubes of variable size within a hyaline and vascular stroma. The tubes are surrounded by medium sized cells with clear cytoplasm and regular nuclei, no pleomorphism or mitotic activity was identified (Fig. 5b and c). An immunohistochemical study was carried out to eliminate a well differentiated NET using chromogranin and synaptophysin. This study did not show tumor cell labeling to these two markers (Fig. 5d).

Postoperative course was uneventful and the patient was discharged from the hospital on the 12-postoperative day. The patient was followed up one month and eight months postoperatively, and we observed that she has recovered completely and remains disease-free.

3. Discussion

The recent improvements in abdominal imaging and invasive diagnostic techniques leads to detect a great proportion of SCN, it is a relatively rare disease, accounting for only 1% to 2% of all pancreatic tumors [5], and between 3–14% of all patients undergoing routine imaging [11].

SCN are actually subdivided histologically into five subtypes: serous microcystic adenomas, serous oligocystic ill-demarcated adenomas, solid-type serous cystadenomas or solid serous adenoma, von Hippel-Lindau disease-associated cystic neoplasms and serous cystadenocarcinomas [7,12,13]. SCA was also divided into four categories based on pathological findings by Kimura and al [5,14] (microcystic type (45–58%), macrocystic type (20–32%), mixed type (16–18%) and Solid type (3–5%).

Table 1 shows the clinical characteristics of, in addition of this case, the 20 previously reported cases of SSCA based on a literature review. SSCA has the same demographic characteristics as the other subtype SCA, it occurs most frequently in elderly women 60 ± 9 years, it was reported in nine males and twelve females (sex ratio 0.75).

SSCA is usually discovered incidentally (52%) or during exams for nonspecific abdominal pain (31%), in the epigastrium (10%) left abdominal pain (5%). It can be located anywhere in the pancreas: head (40%), body (40%), or tail (20%) (Table 1). The median size is 2.8 cm [3–4 cm].

Clinical diagnosis of an SSCA is difficult because it cannot be distinguished from other solid tumors due to its radiologic characteristics. Among all of the previously reported cases including our case, only one case has had the preoperative diagnosis of solid serous adenoma [7,8,15]. Including this case, the most preoperative misdiagnosis is NET (76%), followed by other etiologies of solid tumors (17%) SPPT, pancreatic ductal adenocarcinoma and metastasis.

On CT, SSCA has lower density on unenhanced phase as compared to the surrounding pancreatic tissue more frequently than NET, which was confirmed quantitatively as well by measuring their CT values [16]. Indeed, SSCA showed lower density relative to the surrounding pancreas more frequently than NET also on the delayed phase CT [16]. Characteristic SSCA image findings, such as honeycomb appearance, polycystic pattern, lobularity, central scar and hemorrhage is considered rather rare in SSCA [5,7,14]. On the contrary, Hayashi [16] reported the presence of fibrous capsule can be a sign to discriminate SSCA from NET.

Generally, the mostly accepted management options of pancreatic cystic tumors, is surgery, especially for patients with symptomatic, uncertain diagnosis, or have a high potential of malignant transformation [5,14,17]; however, pancreatic surgical resections are associated with high complication rate. In the other hand, asymptomatic SCA requires only regular observation if a sure preoperative diagnosis is made [7,8,16,18]; however, if there is high suspicion that a pancreatic tumor is an SSCA, based on radiological images, surgery can be minimized to more conservative
procedure [12]. All the previously reported cases of SSCA have been treated by surgery. Various surgical procedures were performed according to the location of the tumor, they are mentioned in 18 patients are shown in Table 1; the procedures included a spleen-preserving distal pancreatectomy (33.3%), a pylorus-preserving pancreaticoduodenectomy (27.7%), a distal pancreatectomy with splenectomy (22.2%) and an enucleation (16.6%). In three (16%) cases by laparoscopy and 15 (83%) by laparotomy. The laparoscopic pancreatectomy offers less morbidity, less intraoperative blood loss, and a shorter length of hospital stay [19–21]. The margin status, operative times, and the fistula rates are similar to open surgery [14,21]. Laparoscopic may be the surgery of choice for patients with benign neoplasms such SSCA [2,19].

### Table 1

| Author          | Year | Age | Sex | Location | Symptoms                | Tumor size (cm) | Preoperative diagnosis | Operative procedure | Outcome/Follow |
|-----------------|------|-----|-----|----------|-------------------------|-----------------|------------------------|---------------------|----------------|
| Perez-Ordonez   | 1996 | 70  | F   | Tail     | Abdominal pain          | 4               | NET                    | DPS                 | 5 years        |
| [21]            |      |     |     |          |                          |                 |                        |                     |                |
| Kosmahl         | 2004 | 50  | M   | Head     | Incidental              | 2               | –                      | PPPPD               |                |
| Yamamoto [6]    | 2004 | 60  | M   | Uncus    | Epigastric pain         | 2               | NET                    | Enucleation         |                |
| Gabata [15]     | 2005 | 59  | F   | Body     | Abdominal pain          | 2               | NET                    | Enucleation         |                |
| Matsumoto [23]  | 2006 | 39  | F   | Body     | Incidental              | 4               | NET                    | PPDD                |                |
| Yamaguchi [24]  | 2006 | 58  | F   | Body     | Incidental              | 2               | Malignant NET          | DP                  |                |
| Reese [1]       | 2006 | 66  | M   | Head/neck| Abdominal pain          | 4               | NET                    | PPPPD               | Diarrhea 1 year  |
| Stern [25]      | 2007 | 62  | M   | Body     | Incidental              | 4.2             | NET, PDA, SPPT, and metastasis | Uneventful 2 months |
| Sanaka [4]      | 2007 | 74  | M   | Body     | Incidental              | 1.6             | Enucleation + YPJ       | Uneventful 2 months |
| Casadei [21]    | 2008 | 59  | F   | Tail     | Abdominal pain          | 4               | NET, SPPT, and Metastasis | DP                  |                |
| Yasuda [18]     | 2011 | 72  | F   | Head     | Incidental              | 1.7             | NET                    | PPPPD               |                |
| Hayashi [16]    | 2012 | 74  | M   | Body     | Incidental              | 4.2             | –                      | –                   |                |
|                 | (2001 and 2009,) | | | | | | | | |
| Lee [9]         | 2013 | 56  | M   | Head     | Not mentioned           | 2.1             | –                      | –                   |                |
| Kishida [7]     | 2014 | 58  | M   | Body     | Not mentioned           | 3.2             | –                      | –                   |                |
| Wu [26]         | 2015 | 48  | M   | Head     | Left abdominal pain     | 2.7             | NET                    | PPPPD               |                |
|                 | 2015 | 65  | M   | Body     | Incidental              | 2.3             | NET                    | Laparoscopic DP     | 2 years        |
| Geramizadeh [8] | 2015 | 68  | F   | Head     | Abdominal pain          | 3               | NET                    | PPPPD               |                |
| Katsourakis [27]| 2016 | 72  | F   | Tail     | Epigastric pain         | 3               | NET, SPPT              | DP                  | PF six months   |
| Current case    | 2017 | 53  | M   | Body     | Abdominal pain          | 3.5             | NET                    | Laparoscopic DPS    | Uneventful 9 months |

NET: Neuroendocrine tumor; SPPT: solid pseudopapillary tumor; PDA: pancreatic ductal adenocarcinoma; DP: distal pancreatectomy without splenectomy, DPS: distal pancreatectomy with splenectomy; YPJ: Roux-en-Y pancreaticojejunostomy; PPPPD: pylorus preserved pancreaticoduodenectomy; PF: pancreatic fistula.

### 4. Conclusion

Solid serous adenoma is an extremely rare subtype of serous pancreatic adenoma. Solid pancreatic tumors are typically associated with malignancy, whereas cystic tumors more often tend to be benign, therefore, it should be considered in the differential diagnosis of solid pancreatic tumors by both clinicians, radiologists, and pathologists in order to avoid aggressive management. A conservative management should be proposed when malignancy signs could be eliminated. Laparoscopic resection offers both the anatomopathological diagnosis and minimally invasive resection for symptomatic tumor.

### Competing interests

The authors declare that they have no competing interests.

### Sources of funding for your research

There is not any sources of funding.

### Ethical approval

Not applicable. No research study involved.

### Consent for publication

Written informed consent was obtained from the patient for publication of this case report and accompanying figures. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

The images are entirely unidentifiable and there are no personal details on the patient reported within the manuscript.

### Author contribution

Mohamed Hamid: Data collection, drafting the paper.
Mohamed Tbouda: carried out the pathologic and immunohistochemical studies and drafted the manuscript.
Anas Mohamed Majbar: revising the manuscript.
Mohamed Raiss, Mohamed Ahallat: Surgeon performing the operation. Data collection. Coordination and helped to draft the manuscript.

### Guarantor

Mohamed Hamid, the corresponding author.
